Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice

BACKGROUND: The FDA-approved small-molecule drug ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib inhibits Bruton’s tyrosine kinase (BTK), a kinase involved in B cell receptor signaling. However, the potential regulation of neuroinflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Nam, Hye Yeon, Nam, Jin Han, Yoon, Gwangho, Lee, Ju-Young, Nam, Youngpyo, Kang, Hye-Jin, Cho, Hyun-Ji, Kim, Jeongyeon, Hoe, Hyang-Sook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145206/
https://www.ncbi.nlm.nih.gov/pubmed/30231870
http://dx.doi.org/10.1186/s12974-018-1308-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145206/
https://www.ncbi.nlm.nih.gov/pubmed/30231870
http://dx.doi.org/10.1186/s12974-018-1308-0

Ejemplares similares